Sewell D, Barry A, Allen S, Fuchs P, McLaughlin J, Pfaller M
Veterans Affairs Medical Center, Portland, Oregon 97201, USA.
Antimicrob Agents Chemother. 1995 Jul;39(7):1591-5. doi: 10.1128/AAC.39.7.1591.
The in vitro activity of WY-49605 (SUN5555) (WY) was compared with those of cefaclor, cefixime, and amoxicillin-clavulanic acid against 2,958 consecutive clinical isolates from five medical centers and 402 respiratory pathogens from 18 other facilities. Most members of the family Enterobacteriaceae were inhibited by WY (MIC at which 50% of the isolates are inhibited [MIC50], < or = 2.0 micrograms/ml). MIC90s of > or = 8.0 micrograms/ml were observed for Enterobacter cloacae, Serratia spp., and Proteus mirabilis. WY was the most active drug against methicillin-susceptible Staphylococcus aureus (MIC90, 0.12 microgram/ml) and other coagulase-negative staphylococci (MIC90, 4.0 micrograms/ml). The four drugs were not active against nonenteric gram-negative bacilli, methicillin-resistant Staphylococcus aureus, and Staphylococcus haemolyticus. At 2.0 micrograms/ml, WY inhibited 82% of Enterococcus faecalis strains and was equal to or superior to the other drugs against streptococci, Haemophilus influenzae, and Moraxella catarrhalis.
将WY-49605(SUN5555)(WY)的体外活性与头孢克洛、头孢克肟和阿莫西林-克拉维酸针对来自五个医疗中心的2958株连续临床分离株以及来自其他18个机构的402株呼吸道病原体的活性进行了比较。肠杆菌科的大多数成员被WY抑制(50%的分离株被抑制时的最低抑菌浓度[MIC50],≤2.0微克/毫升)。阴沟肠杆菌、沙雷菌属和奇异变形杆菌的MIC90≥8.0微克/毫升。WY是对甲氧西林敏感金黄色葡萄球菌(MIC90,0.12微克/毫升)和其他凝固酶阴性葡萄球菌(MIC90,4.0微克/毫升)活性最强的药物。这四种药物对非肠道革兰氏阴性杆菌、耐甲氧西林金黄色葡萄球菌和溶血葡萄球菌无活性。在2.0微克/毫升时,WY抑制了82%的粪肠球菌菌株,并且在针对链球菌、流感嗜血杆菌和卡他莫拉菌方面与其他药物相当或更优。